



MODERN SLAVERY STATEMENT 2025

Introduction & background

Mawdsleys Group Investments Limited publishes this statement pursuant to the Modern Slavery Act 2015 (“MSA”), on behalf of itself and its subsidiaries; Mawdsley-Brooks & Company Limited; MBI Pharma Limited; Mawdsleys Pharmaceuticals DO Brasil LTDA; Mawdsley-Brooks Europe BV; Nadimed BV; Positive Solutions Limited; and Lowry Pharma Limited (together “**Mawdsleys**”), to set out the steps that have been taken to combat modern slavery and human trafficking in our business.

This statement is being issued in Mawdsleys’ 200th anniversary year. As a family-owned business that dates back to 1825, people have always been at the heart of our business. We have built our reputation because of our people and the relationships that we establish and build with our business partners. We pride ourselves on acting ethically and with integrity in all our business dealings and we remain committed to contributing to the prevention and eradication of modern slavery in our workforce and supply chains. Modern slavery, a crime that can involve human trafficking, servitude and forced or compulsory labour, is an abhorrent abuse of human rights and we are fully supportive of the principles of the MSA and intend to play our part in tackling this issue.

Each financial year Mawdsleys publishes a statement setting out the steps it has taken to tackle modern slavery, pursuant to section 54(1) of the MSA. This is Mawdsleys’ seventh statement and relates to the financial year ending **31 March 2025**.

Mawdsleys’ business and supply chains

Mawdsleys specialises in the provision of products and services to the healthcare and pharmaceutical sector, including purchasing, importing, exporting, warehousing, distributing, supplying and delivering medicinal products and devices, and supplying pharmaceutical over-labelling services, IT solutions and regulatory consultancy services. Given the nature of our businesses, the supply of these products and services continues throughout the year. More information about Mawdsleys and its businesses can be found on the website www.mawdsleys.co.uk.

The board of directors of Mawdsleys Group Investments Limited expects the business units to report on the steps that they have taken to address issues of modern slavery.

Our business practices also aim to prevent violations, such as making on time and sufficient payments and acting fairly in requests and demands for goods and services. Ordering standards of our customers are set to ensure that we are not faced with unmanageable deadlines. Many customers have been with Mawdsleys for many years, allowing both parties to develop a greater understanding of each other’s businesses, to gauge pressure points, manage expectations and minimise risk.

Our supply chains fall into the following categories, in respect of which the risks of modern slavery have been assessed as follows:



- **Suppliers of pharmaceutical products.** The products are sourced globally. The pharmaceutical industry is subject to regulation, approval and licenses which facilitates transparency in the supply chain and assists with the due diligence processes.
- **Suppliers of operational goods and services such as IT systems** (UK & US based) and **transport and logistics services** (UK, Brazil, Belgium and Israel based). Most goods and services are sourced from low-risk territories, but Mawdsleys' undertakes due diligence in the normal course.

We seek to agree codes of conduct with manufacturers, suppliers and clients (including compliance with modern slavery laws), which indicates that this is priority for our partners.

Mawdsleys has dedicated in-house HR, H&S, cyber security, procurement and legal departments, complemented by external resources, to ensure compliance with applicable laws and regulations, which employees can access if they have any issues or concerns.

Actions taken in this financial year

During this period the following actions were taken:

- Introduction of a new anti modern slavery policy, which reflects our commitment to acting ethically and with integrity in our business relationships and which sets out internal processes, checks and controls to mitigate potential risks.
- Introduction of questionnaires and enhanced due diligence for new suppliers of GNFR and services to identify the risk of modern slavery in our supply chains.
- Engagement of a dedicated learning and development manager, who will assist in the provision of compliance and governance training, including eLearning for new employees on induction and during periodic refresher training.

Actions for the next financial year

We are committed to improving our practices and in the next financial year we will continue with our efforts to educate staff, partners, customers and suppliers on modern slavery and to generally promote good practice in the prevention and eradication of the issue.

A handwritten signature in black ink that reads 'W Sanders'.

.....

William Sanders, Chief Executive Officer